Treatment Indication	Identifier
Diabetes
Sulfonylureas	27-20-00-20, 27-20-00-27, 27-20-00-30, 27-20-00-40, 27-20-00-50, 27-20-00-60, 27-99-78-02
Biguanides	27-25-00-50, 27-99-25-02, 27-99-50-02, 27-99-70-02, 27-99-80-02
Meglitinide analogues	27-28-00-40, 27-28-00-60
Alpha-glucosidase inhibitors	27-50-00-10, 27-50-00-50
Dipeptidyl peptidase-4 (DPP-4) inhibitors	27-55-00-50, 27-55-00-65, 27-55-00-70, 27-99-30-02
Insulin sensitizing agents	27-60-70-50, 27-60-70-60
Hypertension
Diuretics	37-20-00-10, 37-20-00-20, 37-20-00-30, 37-20-00-80, 37-50-00-10, 37-50-00-20, 37-50-00-30, 37-60-00-10, 37-60-00-20, 37-60-00-25, 37-60-00-40, 37-60-00-50, 37-60-00-55, 37-60-00-60, 37-99-00-02
Beta blockers	33-10-00-10, 33-10-00-25, 33-10-00-30, 33-10-00-40, 33-10-00-45, 33-10-00-50, 33-20-00-10, 33-20-00-20, 33-20-00-21, 33-20-00-22, 33-20-00-30, 33-20-00-40, 33-30-00-07, 33-30-00-10, 36-99-20-02
Calcium channel blockers	34-00-00-03, 34-00-00-10, 34-00-00-13, 34-00-00-15, 34-00-00-18, 34-00-00-20, 34-00-00-24, 34-00-00-30
Angiotensin-converting enzyme inhibitors (ACEs)/angiotensin II receptor blockers (ARBs)/direct renin inhibitors	36-10-00-05, 36-10-00-10, 36-10-00-20, 36-10-00-27, 36-10-00-30, 36-10-00-33, 36-10-00-35, 36-10-00-40, 36-10-00-50, 36-10-00-60, 36-15-00-10, 36-15-00-20, 36-15-00-24, 36-15-00-30, 36-15-00-40, 36-15-00-55, 36-15-00-70, 36-15-00-80, 36-17-00-10, 36-99-15-02, 36-99-18-02, 36-99-30-02, 36-99-40-02, 36-99-45-03, 36-99-60-02, 36-99-67-02, 36-99-68-03
High blood cholesterol
HMG CoA reductase inhibitors	39-40-00-10, 39-40-00-30, 39-40-00-50, 39-40-00-58, 39-40-00-60, 39-40-00-65, 39-40-00-75, 39-40-99-02, 39-99-40-02

Note: Powders and injectables have been excluded from the therapeutic classes.

GPI = Generic Product Identifier; PDC = proportion of days covered.